126 related articles for article (PubMed ID: 9533114)
1. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical models.
Godfrey KR; Tanswell P; Bates RA; Chappell MJ; Madden FN
Biopharm Drug Dispos; 1998 Mar; 19(2):131-40. PubMed ID: 9533114
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens.
Eppler S; Senn T; Gilkerson E; Modi NB
Biopharm Drug Dispos; 1998 Jan; 19(1):31-8. PubMed ID: 9510983
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of plasmatic plasminogen activator in rabbits.
González Rey JR; Cuevas Valdespino M; Cardona M; Díaz A; Gongora C; Pérez B; Sánchez J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):171-6. PubMed ID: 2459015
[TBL] [Abstract][Full Text] [Related]
4. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.
Kamei M; Misono K; Lewis H
Am J Ophthalmol; 1999 Dec; 128(6):739-46. PubMed ID: 10612511
[TBL] [Abstract][Full Text] [Related]
5. Comparative time course of thrombolysis induced by intravenous boluses and infusion of staphylokinase and tissue plasminogen activator in a rabbit arterial thrombosis model.
Helft G; Bara L; Bloch MF; Samama MM
Blood Coagul Fibrinolysis; 1998 Jul; 9(5):411-7. PubMed ID: 9712289
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.
Tanswell P; Heinzel G; Greischel A; Krause J
J Pharmacol Exp Ther; 1990 Oct; 255(1):318-24. PubMed ID: 2120422
[TBL] [Abstract][Full Text] [Related]
7. High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery.
Humphries J; Lattimer C; Smith A; McGuinness CL; Whitton C; Gaffney PJ; Burnand KG
Thromb Res; 1997 Jul; 87(1):123-9. PubMed ID: 9253807
[TBL] [Abstract][Full Text] [Related]
8. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
[TBL] [Abstract][Full Text] [Related]
9. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
10. Localization of tissue plasminogen activator on experimental thrombi in rats.
Kimata H; Nakajima K; Koide T; Yamamoto S; Kondo S
J Pharmacobiodyn; 1990 Dec; 13(12):751-9. PubMed ID: 2129128
[TBL] [Abstract][Full Text] [Related]
11. The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase.
Vachharajani NN; Raymond RH; Shyu WC; Stouffer BC; Boulton DW
Br J Clin Pharmacol; 2011 Nov; 72(5):775-86. PubMed ID: 21545481
[TBL] [Abstract][Full Text] [Related]
12. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
Chen LY; Nichols WW; Saldeen TG; Mehta JL
J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
[TBL] [Abstract][Full Text] [Related]
13. Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
Schneider J; Friderichs E; Günzler WA; Flohé L
Thromb Res; 1989 Oct; 56(1):59-65. PubMed ID: 2512686
[TBL] [Abstract][Full Text] [Related]
14. Tissue plasminogen activator levels after single intracisternal injection in patients with subarachnoid hemorrhage.
Jito J; Nakasu Y; Nakasu S; Hatsuda N; Matsuda M
Neurol Med Chir (Tokyo); 2004 Feb; 44(2):55-60; discussion 60. PubMed ID: 15018324
[TBL] [Abstract][Full Text] [Related]
15. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
[TBL] [Abstract][Full Text] [Related]
16. Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats.
Martin U; Doerge L; Stegmeier K; Müller-Beckmann B
Drug Metab Dispos; 1996 Mar; 24(3):288-92. PubMed ID: 8820418
[TBL] [Abstract][Full Text] [Related]
17. Concomitant nitroglycerin and rTPA.
Massel D
Am Heart J; 1997 Jun; 133(6):713-4. PubMed ID: 9200401
[No Abstract] [Full Text] [Related]
18. Re: augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude.
Roy S
J Vasc Interv Radiol; 2001 Feb; 12(2):264-6. PubMed ID: 11265895
[No Abstract] [Full Text] [Related]
19. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
[TBL] [Abstract][Full Text] [Related]
20. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Lucore CL; Fujii S; Sobel BE
Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
